Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.49 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.47 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | CCR3 | P51677 | 2/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5658226 | 0.88 | DRD2 (0.49) | DRD2HRH3CARM1PRMT6CCR3 | |
| SCHEMBL26306413 | 0.82 | DRD2 (0.58) | DRD2CARM1PRMT6 | |
| SCHEMBL5337033 | 0.82 | DRD2 (0.50) | DRD2CCR3CCR1 | |
| SCHEMBL3074452 | 0.82 | DRD2 (0.56) | DRD2 | |
| SCHEMBL3271236 | 0.82 | ADRB2 (0.42) | DRD2HRH3ADRB2CCR3CCR1 | |
| SCHEMBL3074454 | 0.82 | DRD2 (0.56) | DRD2 | |
| SCHEMBL3271240 | 0.82 | ADRB2 (0.42) | DRD2HRH3ADRB2CCR3CCR1 | |
| SCHEMBL25570361 | 0.81 | DRD2 (0.50) | DRD2CARM1PRMT6CCR3CCNT1 | |
| SCHEMBL23142741 | 0.80 | DDB1 (0.49) | DRD2HRH3CARM1PRMT6CCR3 | |
| SCHEMBL7481961 | 0.80 | GPR119 (0.47) | ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | DRD2 69/4885HRH3 2732/4885CARM1 3839/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | DRD2 69/4885HRH3 2732/4885CARM1 3839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.